enGene’s CEO Ron Cooper and CSO Anthony Cheung were featured in a FirstWord Pharma Q&A where they discussed our investigational therapy for non-muscle invasive bladder cancer (NMIBC). Learn more about our commitment to developing innovative, non-viral genetic medicines to improve the quality of life for people with urological cancers.
